Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients

Metzner, Karin J; Scherrer, Alexandra U; von Wyl, Viktor; Böni, Jürg; Yerly Ferrillo, Sabine; Klimkait, Thomas; Aubert, Vincent; Furrer, Hansjakob; Hirsch, Hans H; Vernazza, Pietro L; Cavassini, Matthias; Calmy, Alexandra; Bernasconi, Enos; Weber, Rainer; Günthard, Huldrych F

doi:10.1097/QAD.0000000000000397

Scientific article

English

Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients

ContributorsMetzner, Karin J; Scherrer, Alexandra U; von Wyl, Viktor; Böni, Jürg; Yerly Ferrillo, Sabine; Klimkait, Thomas; Aubert, Vincent; Furrer, Hansjakob; Hirsch, Hans H; Vernazza, Pietro L; Cavassini, Matthias; Calmy, Alexandra

; Bernasconi, Enos; Weber, Rainer; Günthard, Huldrych F

Published inAIDS, vol. 28, no. 15, p. 2231-2239

Publication date2014

Abstract

The presence of minority nonnucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-1 variants prior to antiretroviral therapy (ART) has been linked to virologic failure in treatment-naive patients.

Keywords

Adult
Alleles
Anti-Retroviral Agents/therapeutic use
Drug Resistance, Viral
Female
Genotyping Techniques/methods
HIV Infections/virology
HIV Reverse Transcriptase/genetics
HIV-1/enzymology/genetics/isolation & purification
Humans
Male
Microbial Sensitivity Tests/methods
Middle Aged
Mutation, Missense
Retrospective Studies
Treatment Outcome

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

Citation (ISO format)

METZNER, Karin J et al. Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients. In: AIDS, 2014, vol. 28, n° 15, p. 2231–2239. doi: 10.1097/QAD.0000000000000397

Article (Published version)

Identifiers

PID : unige:74401
DOI : 10.1097/QAD.0000000000000397
PMID : 25036184

Journal ISSN0269-9370

537views

0downloads

Creation09/07/2015 14:28:00

First validation09/07/2015 14:28:00

Update time14/03/2023 23:30:35

Status update14/03/2023 23:30:34

Last indexation31/10/2024 00:56:56

Archive ouverte UNIGE

Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients

The presence of minority nonnucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-1 variants prior to antiretroviral therapy (ART) has been linked to virologic failure in treatment-naive patients.

Technical informations